Patents by Inventor Frank Schnieders
Frank Schnieders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250127931Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.Type: ApplicationFiled: November 4, 2024Publication date: April 24, 2025Applicant: Provecs Medical GmbHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
-
Patent number: 12133898Abstract: A method of treating cancer, a viral infection and/or an immune system disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a vector, wherein the vector comprises (a) nucleic acid sequences encoding 4-1BB ligand (4-1BBL), single chain IL-12 (scIL-12) and IL-2, and (b) at least one regulatory nucleic acid sequence providing for an increased expression level of 4-1BBL as compared to the expression levels of scIL-12 and IL-2, and other related methods.Type: GrantFiled: April 1, 2021Date of Patent: November 5, 2024Assignee: PROVECS MEDICAL GMBHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
-
Publication number: 20230042961Abstract: A fungicidal composition containing a fungicidally effective amount of the compound of Formula I, 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)propyl)pyridin-3- yl)oxy)benzonitrile for use on fungal diseases of cereals. Additionally, this disclosure concerns a fungicidal composition containing (a) the compound of Formula I, 4-((6-(2-(2,4-difluorophenyl)-1,1-difiuoro-2-hydroxy-3-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and (b) the compound of Formula II, (S)-1,1-bis(4-fluorophenyl)propan-2-yl (3-acetoxy-4-methoxypicolinoyl)-L-alaninate, for control of fungal diseases of cereals.Type: ApplicationFiled: November 22, 2017Publication date: February 9, 2023Inventors: Akos Biro, Mark Fairfax, Iuliia Kovalova, Michel Luras, Courtney Gallup, Romain Colombo, Frank Schnieder
-
Publication number: 20210220486Abstract: A method of treating cancer, a viral infection and/or an immune system disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a vector, wherein the vector comprises (a) nucleic acid sequences encoding 4-1BB ligand (4-1BBL), single chain IL-12 (scIL-12) and IL-2, and (b) at least one regulatory nucleic acid sequence providing for an increased expression level of 4-1BBL as compared to the expression levels of scIL-12 and IL-2, and other related methods.Type: ApplicationFiled: April 1, 2021Publication date: July 22, 2021Applicant: Provecs Medical GmbHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
-
Patent number: 10994027Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.Type: GrantFiled: February 23, 2017Date of Patent: May 4, 2021Assignee: Provecs Medical GmbHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
-
Publication number: 20190297888Abstract: A fungicidal composition containing a fungicidally effective amount of a compound of Formula I, 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1H-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile for use on fungal diseases of cereals. Additionally, this disclosure concerns a fungicidal composition containing (a) a compound of Formula I, 4-((6-(2-(2,4-difluorophenyl)-1, 1-difluoro-2-hydroxy-3-(5-mercapto-1H-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and (b) a succinate dehydrogenase-inhibitor, for example fluxapyroxad, benzovindiflupyr, penthiopyrad, isopyrazam, bixafen, boscalid, penflufen, and fluopyram, for control of fungal diseases of cereals.Type: ApplicationFiled: November 22, 2017Publication date: October 3, 2019Inventors: Mark Fairfax, Courtney Gallup, Romain Colombo, Akos Biro, Frank Schnieder, Enrique Lopez Romero
-
Publication number: 20190297890Abstract: A fungicidal composition containing a fungicidally effective amount of a compound of Formula I, 4-((6-(2-(2,4-difluo-rophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)propyl)pyridin-3- yl)oxy)benzonitrile for use on fungal diseases of cereals. Additionally, this disclosure concerns a fungicidal composition containing (a) a compound of Formula I, 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1- yl)propyl)pyridin-3-yl)oxy)benzonitrile and (b) chlorothalonil, for control of fungal diseases of cereals.Type: ApplicationFiled: November 22, 2017Publication date: October 3, 2019Inventors: Romain Colombo, Frank Schnieder, Mark Fairfax, Courtney Gallup
-
Publication number: 20190274303Abstract: The present disclosure is related to the field of agrochemicals, including compound I and it's use to control fungal diseases of barley. Compound (I).Type: ApplicationFiled: November 22, 2017Publication date: September 12, 2019Inventors: Mark Fairfax, Frank Schnieder, Rebecca Hilton, Enrique Lopez Romero, Gary D. Gustafson, Javier Delgado, Courtney Gallup
-
Publication number: 20190046664Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.Type: ApplicationFiled: February 23, 2017Publication date: February 14, 2019Applicant: Provecs Medical GmbHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleishhauer
-
Patent number: 8067227Abstract: The invention relates to viral vectors comprising nucleic acid sequences coding for single chain interleukin-12 (single chain IL-12 or scIL12) and a costimulator protein, and to the use of vectors for gene therapy, especially for the treatment of tumors. The invention further relates to adenoviral vectors containing nucleic acid sequences having a sequence homology of at least 90% in relation to the sequence displayed in FIGS. 19 and 20 (IL-12), in FIG. 21 (4-1BB ligand) and in FIG. 22 (IL-2) and optionally also one of the sequences displayed in FIG. 23A (B7-1) or 23B (B7-2).Type: GrantFiled: October 10, 2003Date of Patent: November 29, 2011Assignee: Universitätsklinikum Hamburg-EppendorfInventors: Reinhard Wähler, Frank Schnieders
-
Publication number: 20060153805Abstract: The invention relates to viral vectors comprising nucleic acid sequences coding for single chain interleukin-12 (single chain IL-12 or scIL 12) and a costimulator protein, and to the use of said vectors for gene therapy, especially for the treatment of tumours. The invention further relates to adenoviral vectors containing nucleic acid sequences having a sequence homology of at least 90% in relation to the sequence displayed in FIGS. 19 and 20 (IL-12), in FIG. 21 (4-1BB ligand) and in FIG. 22 (IL-2) and optionally also one of the sequences displayed in FIG. 23A (B7-1) or 23B (B7-2).Type: ApplicationFiled: October 10, 2003Publication date: July 13, 2006Inventors: Reinhard Walhler, Frank Schnieders
-
Publication number: 20030191744Abstract: The invention relates to a computer system for knowledge management with a first database means for storing documents and meta-information on documents, a second database means for storing user data, a means for accessing an external data source for loading external documents and storing external documents in the first database means, a first program means for the inputting a search request by an internal client computer, a second program means for adding a document to the first database means by the internal client computer, a third program means for inputting an evaluation for a document of the first database means by an internal client computer, a fourth program means for awarding and storing bonus points to the credit of a user as a function of user behavior.Type: ApplicationFiled: April 4, 2003Publication date: October 9, 2003Inventors: Torsten Derr, Paul-Johannes Mayska, Hakan Colakoglu, Frank Schnieders, Thomas Kraft, Georg Heger, Ralf Pakull